Pharmacokinetics and pharmacodynamics in toxicology

Xenobiotica

Volumn 27, Issue 5, 1997, Pages 513-525

  Smith, D A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SALAZOSULFAPYRIDINE; SULFAPYRIDINE; UNCLASSIFIED DRUG; ZAMIFENACIN;

ANIMAL EXPERIMENT; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; HUMAN; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; RAT; REVIEW; SPECIES DIFFERENCE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACOKINETICS; PHARMACOLOGY; SPECIES SPECIFICITY; TOXICOLOGY;

EID: 0030969001     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240479     Document Type: Review

References (46)

1. 2μ-globulin nephropathy. Quantitative Structure-Activity Relationships, 13, 275-280.
2. BEAUMONT, K. C., MACRAE, P. V., MILLER, C. M., SMITH, D. A. and WRIGHT, P., 1994, Pharmacokinetics of zamifenacin in man and animals; species differences in plasma protein binding. British Journal of Clinical Pharmacology, 38, 179P.
3. 2μ-globulin nephropathy. Annual Review of Pharmacology and Toxicology, 30, 349-367.
4. BOCSKEI, Z., GROOM, C. R., FLOWER, D. R., WRIGHT, C. E., PHILLIPS, S. K., CAVAGGIONI, A., FINDLAY, J. B. and NORTH, A. C., 1992, Pheromone binding to two rodent urinary proteins revealed by X-ray crystallography. Nature, 360, 186-188.
5. BOELSTERLI, U. A., 1993, Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metabolism Reviews, 25, 395-451.
6. + channel. Circulation Research, 72, 707-714.
7. CLARK, B. and SMITH, D. A., 1984, Pharmacokinetics and toxicity testing. Critical Reviews in Toxicology, 12, 343-385.
8. CLARK, B. and SMITH, D. A., 1988, Drug metabolism studies in safety evaluation. In Progress in Drug Metabolism, vol. 11, edited by G. G. Gibson (London: Taylor & Francis), pp. 175-216.
9. DAIN, J. G. and JAFFE, J. M., 1988, Effect of diet and gavage on the absorption and metabolism of fluperlapine in the rat. Drug Metabolism and Disposition, 16, 238-242.
10. D'AMATO, R. J., LOUGHNAN, M. S., FLYNN, E., and FOLKMAN, J., 1994, Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences, 91, 4082-4085.
11. DUIGNAN, D., SIPES, I. G., CIACCIO, P. J. and HALPERT, J. R., 1988, The metabolism of xenobiotics and endogenous compounds by the constitutive dog liver cytochrome P-450 PBD-2. Archives of Biochemistry and Biophysics, 267, 294-304.
12. FENTON, J. H. and FRY, J. R., 1993, Species differences in the metabolism and hepatotoxicity of coumarin. Comparative Biochemistry and Physiology, 104C, 1-8.
13. FESTING, M. F., 1993, Genetic variation in outbred rats and mice and its implications for toxicological screening. Journal of Experimental Animal Science, 35, 210-20.
14. FUKATA, H., UCHIDA, T., KOMORI, M., KITADA, M. and KAMATAKI, T., 1992, Toxicological significance of dog liver cytochrome P-450; examination with the enzyme expressed in Saccharomyces cerevisiae using recombinant expression plasmid. Mutation Research, 269, 97-105.
15. HARD, G. C. and WHYSNER, J., 1994, Risk assessment of d-limonene: an example of male-specific renal tumorigens. Critical Reviews in Toxicology, 24, 231-254.
16. IMAOKA, S., FUJITA, S. and FUNAE, Y., 1991, Age dependent expression of cytochrome P-450's in rat liver. Biochimica et Biophysica Acta, 1097, 187-192.
17. KIMURA, M., TAKAHASHI, H., OHTAKE, T., SAKO, T., HISHIDA, A., NISHIMURA, M. and HONDA, N., 1993, Interstrain difference in murine daunomycin-induced nephrosis. Nephron, 63, 193-198.
18. KOMORI, M., SHIMADA, H., MIURA, T. and KAMATAKI, T., 1989, Interspecies homology of liver microsomal cytochrome P-450, a form of dog cytochrome P-450 (P-450-D1) cross reactive with antibodies to rat P-450-male. Biochemical Pharmacology, 38, 235-245.
19. LEHMAN-MCKEEMAN, L. D. and CAUDILL, D., 1994, D-limonene induced hyaline droplet nephropathy in alpha 2μ-globulin transgenic mice. Fundamental in Applied Toxicology, 23, 562-568.
20. LIN, J. H., CHEN, I. W. and KING, J., 1992, Dose dependent toxicokinetics of L-689, 502 a potent human immunodeficiency virus protease inhibitor in rats and dogs. Journal of Pharmacology and Experimental Therapeutics, 263, 105-111.
21. MACDONALD, J. S., PETER, C. P., DUCHAI, D. M., STUBBS, R. J., GERMERSHAVEN, J. I. and ROBERTS, A. W., 1989, Toxicity of the HMG-coenzyme A reductase inhibitor lovastatin to rabbit. Journal of Pharmacology and Experimental Therapeutics, 248, 498-505.
22. MISENHEIMER, T. M. and SUTTIE, J. W., 1990, Warfarin resistance in the Chicago strain of rats. Biochemical Pharmacology, 40, 2079-2084.
23. MONRO, A. M., 1990, Interspecies comparisons in toxicology: the utility and futility of plasma concentrations of the test substance. Regulatory Toxicology and Pharmacology, 12, 137-160.
24. MONRO, A. M., 1994, Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic response. Journal of Pharmacokinetics and Biopharmaceutics, 22, 41-57.
25. MORGAN, D. G., KELVIN, A. S., KINTER, L. B., FISH, C. J., KERNS, W. D. and RHODES, G., 1994, The application of toxicokinetic data to dosage selection in toxicology studies. Toxicologic Pathology, 22, 112-123.
26. NAKAMURA, A., YAMAMOTO, Y., TAKASAKI, T., SUGIMOTO, C., MASUDA, M., KAZUSAKA, A. and FUKITA, S., 1995, Purification and characterisation of a dog cytochrome P-450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody. Drug Metabolism and Disposition, 23, 1268-1273.
27. NEDELCHEVA, V. and GUT, I., 1994, P-450 in rat and man. Methods of investigation, substrate specificities and relevance to cancer. Xenobiotica, 24, 1151-1175.
28. NEUBERT, D., HEGER, W., BREMER, D., FRANKUS, E., HELM F.-CH. and MERKER, H.-J., 1987, Some studies on the areneoxide hypothesis of the teratogenic action of thalidomide. In Pharmacokinetics in Teratogenesis, vol. 1, edited by H. Nau and W. J. Scott (Boca Raton: CRC Press), pp. 177-180.
29. NEVILLE, C. F., NINOMIYA, S., SHIMADA, N., KAMATAKI, T., IMAOKA, S. and FUNAE, Y., 1993, Characterisation of the specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats. Biochemical Pharmacology, 45, 59-65.
30. NIWA, T., KANEKO, H., NARITOMI, Y., TOGAWA, A., SHIRAGA, T., IWASAKI, K., TOZUKA, Z. and HATA, T., 1995, Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat, dog and monkey. Xenobiotica, 25, 1041-1049.
31. PRICE, E. M. and LINGREL, J. B., 1988, Structure-function relationships in the Na, K-ATPase alpha subunit: site directed mutagenesis of glutamine-111 to arginine and asparagine-122 to aspartic acid generates an ouabain-resistant enzyme. Biochemistry, 27, 8400-8408.
32. RUCH, S., KENNEDY, R. H. and SEIFEN, E., 1992, Digoxin cardiotoxicity in ageing anaesthetized F344 rats. Mechanisms of Ageing and Development, 65, 199-216.
33. SAKAMOTO, K., KIRITA, S., BABA, T., NAKAMURA, Y., YAMAZOE, Y., KATO, R., TAKANAKA, A. and MATSUBARA, T., 1995, A new cytochrome P-450 form belonging to the CYP2D in dog liver microsomes purification, CDNA cloning and enzyme characterisation. Archives of Biochemistry and Biophysics, 319, 372-382.
34. SHIRAGA, T., IWASAKI, K., NOZAKI, K., TAMURA, T., YAMAZOE, Y., KATO, R. and TAKANAKA, A., 1994, Isolation and characterisation of four cytochrome P-450 isozymes from untreated and phenobarbital treated beagle dogs. Biological and Pharmaceutical Bulletin, 17, 22-28.
35. SMITH, D. A., HUMPHREY, M. J. and CHARUEL, C., 1990, Design of toxicokinetic studies. Xenobiotica, 20, 1187-1199.
36. SMITH, D. A., 1993, Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment. European Journal of Drug Metabolism and Pharmacokinetics, 18, 31-39.
37. SMITH, D. A., 1991, Species differences in metabolism and pharmacokinetics: are we close to an understanding. Drug Metabolism Reviews, 23, 355-373.
38. SMITH, D. A., BROWN, K. and NEALE, M. G., 1985-6, Chromone-2 carboxylic acids: roles of acidity and lipophilicity in drug disposition. Drug Metabolism Reviews, 16, 365-388.
39. SMITH, D. A. and JONES, B. C., 1992, Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology, 44, 2089-2098.
40. SMITH, R. L., 1988, The role of metabolism and disposition studies in the safety assessment of pharmaceuticals. Xenobiotica, 18, 89-96.
41. SUSICK, R. L. and WOOLF, T., 1993, Application of toxicokinetic principles in the development of antiatherosclerotic compounds. In Drug Toxicokinetics, edited by P. G. Welling and F. A. de la Iglesia (New York: Marcel Dekker), pp. 305-324.
42. TARLOFF, J. B., GOLDSTEIN, R. S. and HOOK, J. B., 1989, Strain differences in acetaminophen nephrotoxicity in rats: role of pharmacokinetics. Toxicology, 56, 167-177.
43. +) adenosine triphosphatase from difference species. Biochemical Pharmacology, 21, 1553-1560.
44. TOWNSEND, M. G., ODAM, E. M. and PAGE, J. M. J., 1975, Studies on the microsomal drug metabolism system in warfarin-resistant and -susceptible rats. Biochemical Pharmacology, 24, 729-735.
45. WANG, P., LUTHIN, G. R. and RUGGIERIE, M. R., 1995, Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. Journal of Pharmacological and Experimental Therapeutics, 273, 959-966.
46. ZHENG, W., WINTER, S. M., MAYERSOHN, M., BISHOP, J. B. and SIPES, I. G., 1993, Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. Drug Metabolism and Disposition, 21, 1091-1097.